BioSight
Companies
Enliven Therapeutics, Inc. logo

ELVN

NASDAQBOULDER, CO
Enliven Therapeutics, Inc.

Enliven Therapeutics develops small-molecule drug candidates targeting oncology, with a lead program called ELVN-001 that targets BCR-ABL in blood cancers. The company is advancing ELVN-001 through clinical trials with plans for regulatory filings, while exploring additional product candidates in development. Enliven is in the clinical-stage development phase, working toward FDA approval and eventual commercialization of its pipeline.

Price history not yet available for ELVN.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar